Wednesday, August 28, 2019 12:40:50 PM
We can then add that upcoming medical journal to other recent events including:
• today’s robust & positive S1R publication in Frontiers (which references 2-73 and 3-71 specifically); and factor in all of the other recent positives including
• our new CMO in 2019 Dr Kaufmann (Rett Syndrome leading researcher),
• key job postings at indeed.com last week,
• our 2019 announced ERP Biomarker consortium with BP and Cognision
• our leadership role in precision medicine in the CNS space,
• Rett Syndrome trial DSMB review outcome received as a positive sign (per Janney Montgomery Scott analyst Yun Zhong),
• purchase of $1MM of 2-73 inventory
• “we are working with specialists” to develop a commercial name for 2-73 Blarcamesine,
• RS and PDD and AD researchers/participants asking to extend treatment in current trials and the ph2a trial,
• 4-5 years of safety with generally mild AE (indicative of compound crossing the BBB per Dr M)
• positive reported RWE in ph2a, as referenced in presentations and trial PI Macfarlane media quotes
• AD promising-efficacy especially when dose/blood concentration correlated per Ariana analysis
• according to q3 conf call, the Company believes (awaiting confirmation in current trials) that 2-73/blarcamesine is able to correlate with an improvement in gut microbiata levels (patients had a higher diversity in the gut)
Are US regulators being made aware of Anavex’s progress & the growing body of scientific support for our MOA across a WIDE RANGE of debilitating medical diseases and conditions??
If so, and in light of our long-term safety record and mild side effects and positive real world evidence, combined with the need to treat AD at the earliest stage possible, HOW/WHY are we not yet granted an accelerated approval pathway by the US Food & Drug Administration?
Where is the contradictory scientific evidence negating our MOA?
I can only find solid SUPPORT.
To invoke the great philosopher Michael Stipe from REM, it seems we are pushing an elephant up the stairs.
Pressure is building though, and it’ll likely come from the outside. Our trial patients/caregivers and trial PI’s & S1R worldwide researchers’ influence may someday tilt the scale.
https://www.frontiersin.org/articles/10.3389/fnins.2019.00862/full?utm_source=F-NTF&utm_medium=EMLX&utm_campaign=PRD_FEOPS_20170000_ARTICLE
Jobs at Anavex, driven by innovation, problem-solving and fast growth vision:https://www.indeed.com/jobs?q=anavex&l=
https://erpbiomarkers.org/
https://www.nasdaq.com/aspx/call-transcript.aspx?StoryId=4282937&Title=anavex-life-sciences-avxl-ceo-christopher-missling-on-q3-2019-results-earnings-call-transcript
https://www.frontiersin.org/articles/10.3389/fimmu.2018.02325/full#h2
[https://www.google.com/amp/s/finance.yahoo.com/amphtml/news/congress-big-pharma-money-123757664.html
“I’m really much more concerned because Congress is supposed to have oversight for the FDA,” Brown said. “If the FDA isn’t going to hold pharma accountable, and Congress is getting paid to not hold pharma accountable, then it really doesn’t matter who the president is because it’s really about Congress.”]
Recent AVXL News
- Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia • GlobeNewswire Inc. • 10/17/2024 11:30:00 AM
- ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management • InvestorsHub NewsWire • 10/15/2024 12:21:48 PM
- ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today • InvestorsHub NewsWire • 10/01/2024 11:00:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024 • GlobeNewswire Inc. • 09/03/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 09:21:05 PM
- Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024 • GlobeNewswire Inc. • 08/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 09:20:53 PM
- Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference • GlobeNewswire Inc. • 07/30/2024 11:30:00 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/29/2024 09:21:49 PM
- Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference • GlobeNewswire Inc. • 07/28/2024 09:00:00 PM
- Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference • GlobeNewswire Inc. • 06/20/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 11:30:10 AM
- Anavex Life Sciences Announces Expansion of Leadership Team • GlobeNewswire Inc. • 05/22/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/17/2024 10:01:00 AM
- Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ • GlobeNewswire Inc. • 05/14/2024 11:30:00 AM
- Shareholders that lost money on Anavex Life Sciences Corporation(AVXL) Urged to Join Class Action - Contact The Gross Law Firm to Learn More • PR Newswire (US) • 05/10/2024 09:45:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:35:55 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:00:30 PM
- Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/09/2024 11:30:00 AM
- The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Anavex Life Sciences Corporation(AVXL) Shareholders • PR Newswire (US) • 05/07/2024 09:45:00 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/06/2024 10:03:33 AM
- Anavex Life Sciences Corporation Sued for Securities Law Violations - Contact The Gross Law Firm Before May 13, 2024 to Discuss Your Rights - AVXL • PR Newswire (US) • 05/03/2024 09:45:00 AM
- Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024 • GlobeNewswire Inc. • 05/02/2024 11:30:00 AM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM